Press Releases

May 6, 2021
– Bylvay TM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU– – Completed global commercial agreements for two key top ten markets – – ASSERT & BOLD Phase 3 studies enrolling and on track – – Advanced novel MOA ASBTi A3907 into Phase 1 study – – Recent CTO
April 29, 2021
Conference call and webcast to be held at 10:00 a.m. ET BOSTON , April 29, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and
March 25, 2021
– Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome – – EMA & FDA reviewing odevixibat for PFIC, currently no plans for FDA advisory committee meeting – – Achievement of important